Turkiye Klinikleri Journal of Internal Medicine

.: REVIEW
Çölyak Hastalığında Moleküler Tanı Testleri ve Farmakolojik Tedavi Yaklaşımları: Sistematik Derleme
Molecular Diagnostic Tests and Pharmacological Therapy Approaches in Celiac Disease: A Systematic Review
Münevver Nazlıcan ZENGİNa, Yasemin ŞAHİNa, Hande YÜCEb, Osman ÇİFTÇİa
aPamukkale Üniversitesi Tıp Fakültesi, Tıbbi Farmakoloji ABD, Denizli, Türkiye
bİnönü Üniversitesi Eczacılık Fakültesi, Farmasötik Toksikoloji ABD, Malatya, Türkiye
Turkiye Klinikleri J Intern Med. 2022;7(2/3):63-73
doi: 10.5336/intermed.2022-90367
Article Language: TR
Full Text
ÖZET
 Otoimmün hastalıklar otoantikor üretimi ve doku yıkımı ile karakterize olup kalıtsal ve çevresel faktörlerden etkilenmektedir. Çölyak hastalığı genetik olarak yatkın olan bireylerde diyetle alınan glutene karşı duyarlılık sonucunda ortaya çıkan immünolojik olarak gelişen inflamatuvar yanıt sonucu intestinal villuslarda hasar ve klinik olarak malabsorpsiyona neden olan kronik otoimmün bir hastalıktır. İnflamasyon sürecien spesifik antikor üretimi eşilik eder ve gastrointestinal semptomlarla birlikte çeşitli bağırsak dışı semptomlara yol açar. Hastalığın dünyadaki prevalansının %1 olduğu tahmin edilmekle birlikte hastalığın tanısında kullanılan duyarlı ve spesifik testlerinin kullanılması nedeniyle bildirilen vaka sayısı gün geçtikçe artmaktadır. Hastalığın temelinde insan lökosit antijeni (HLA)-DQA1/B1 lokuslarındaki allellerle kodlanan HLA sınıf II protein moleküllerinin olduğu bilinmektedir. Klinik testlerde moleküler teşhis yöntemlerinde en çok HLA- DQA1/ DQB1, HLA-DRB1, HLA-DRA, CTLA4 ve MYO9B gen bölgeleri taranmaktadır. Hastalığın tedavisinde farmakolojik bir yaklaşım bulunmamakla birlikte, glutensiz diyet etkin olarak kabul edilen tek tedavi yöntemidir. Alternatif veya destekleyici bir tedavi yönteminin bulunması için preklinik ve klinik olarak oral endopeptidazlar, transglutaminaz inhibitörleri, glukokortikoidler, mikrobiyota ilişkili tedaviler, gluten bağlayıcı polimerler, immünomodülatör peptitler gibi farklı tedaviler denenmektedir. Glutene karşı bağışıklık toleransını yeniden sağlamak veya gluten kaynaklı bağışıklık aktivasyonu engellemek amacıyla potansiyel terapötik ajanların araştırmaları devam etmektedir. Yazılan derlemede çölyak hastalarına yönelik etkili bir terapötik yaklaşım bulmak amacıyla, literatürde yer alan güncel çalışmalar gözden geçirilmiştir.

Anahtar Kelimeler: Çölyak hastalığı; otoimmünite; genetik test; ilaç tedavisi
ABSTRACT
 Autoimmune diseases are characterized by autoantibody production and tissue destruction and are affected by hereditary and environmental factors. Celiac disease is a chronic autoimmune disease that causes damage to intestinal villi and clinical malabsorption as a result of an immunologically developed inflammatory response resulting from sensitivity to dietary gluten in individuals who are genetically predisposed. The inflammatory process is accompanied by the production of specific antibodies and causes a variety of extra-intestinal symptoms along with gastrointestinal symptoms. Although the prevalence of the disease in the world is estimated at 1%, the number of reported cases is increasing day by day due to the use of sensitive and specific tests in the diagnosis of the disease. It is known that HLA class II protein molecules encoded by the alleles in the human leukocyte antigen (HLA)-DQA1/B1 loci are the basis of the disease. In clinical tests, molecular diagnostic methods mostly scan the HLA-DQA1/DQB1, HLA-DRB1, HLA-DRA, CTLA4, and MYO9B gene regions. Although there is no pharmacological approach to the treatment of the disease, a gluten-free diet is the only effective treatment method. In order to find an alternative or supportive treatment method, different treatments such as oral endopeptidases, transglutaminase inhibitors, glucocorticoids, microbiota-related treatments, gluten-binding polymers, and immunomodulatory peptides are tried both preclinically and clinically. Research continues for potential therapeutic agents to restore immune tolerance to gluten or to inhibit gluten-induced immune activation. In this review, current studies in the literature were reviewed in order to find an effective therapeutic approach for celiac patients.

Keywords: Celiac disease; autoimmunity; genetic testing; drug therapy
REFERENCES:
  1. Ludvigsson JF, Leffler DA, Bai JC, Biagi F, Fasano A, Green PH, etal. The Oslo definitions for coeliac disease and related terms. Gut. 2013;62(1):43-52. [Crossref]  [PubMed]  [PMC] 
  2. Sahin Y. Celiac disease in children: a review of the literature. World J Clin Pediatr. 2021;10(4):53-71. [Crossref]  [PubMed]  [PMC] 
  3. Singh P, Arora A, Strand TA, Leffler DA, Catassi C, Green PH, et al. Global Prevalence of Celiac Disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(6):823-36.e2. [Crossref]  [PubMed] 
  4. Tunçer E, Yabancı Ayhan N. Çölyak hastalığında mikro besin ögeleri [Micronutrients deficiencies and nutritional recommendations in celiac disease]. Bandırma Onyedi Eylül Üniversitesi Sağlık Bilimleri ve Araştırmaları Dergisi. 2021;3(1). [Crossref] 
  5. King JA, Jeong J, Underwood FE, Quan J, Panaccione N, Windsor JW, et al. Incidence of celiac disease is increasing over time: a systematic review and meta-analysis. Am J Gastroenterol. 2020;115(4):507-25. [Crossref]  [PubMed] 
  6. Yıldırım H, Öngün Yılmaz H. Çölyak hastalığı ile tamamlayıcı beslenme, anne sütü ve emzirme ilişkisi [The relationship between celiac disease and complementary feeding, breast milk and breastfeeding]. Türkiye Sağlık Bilimleri ve Araştırmaları Dergisi. 2021;4(3):85-98. [Crossref] 
  7. Shewry PR, Halford NG, Belton PS, Tatham AS. The structure and properties of gluten: an elastic protein from wheat grain. Philos Trans R Soc Lond B Biol Sci. 2002;357(1418):133-42. [Crossref]  [PubMed]  [PMC] 
  8. Guandalini S, Discepolo V. Celiac disease. In: Guandalini S, Dhawan A, Branski D, eds. Textbook of Pediatric Gastroenterology, Hepatology and Nutrition: A Comprehensive Guide to Practice. 1st ed. Switzerland: Springer International Publishing; 2016. p.425-69.
  9. Leonard MM, Sapone A, Catassi C, Fasano A. Celiac disease and nonceliac gluten sensitivity: a review. JAMA. 2017;318(7):647-56. [Crossref]  [PubMed] 
  10. Reilly NR, Aguilar K, Hassid BG, Cheng J, Defelice AR, Kazlow P, et al. Celiac disease in normal-weight and overweight children: clinical features and growth outcomes following a gluten-free diet. J Pediatr Gastroenterol Nutr. 2011;53(5):528-31. [Crossref]  [PubMed] 
  11. Baydoun A, Maakaron JE, Halawi H, Abou Rahal J, Taher AT. Hematological manifestations of celiac disease. Scand J Gastroenterol. 2012;47(12):1401-11. [Crossref]  [PubMed] 
  12. Kamycheva E, Goto T, Camargo CA Jr. Celiac disease is associated with reduced bone mineral density and increased FRAX scores in the US National Health and Nutrition Examination Survey. Osteoporos Int. 2017;28(3):781-90. [Crossref]  [PubMed] 
  13. Torres MI, Palomeque T, Lorite P. Celiac disease and other autoimmune disorders. In: Torres MI, Lorite P, eds. Autoimmunity- Pathogenesis, Clinical Aspects and Therapy of Specific Autoimmune Diseases. InTech; 2015. [Crossref] 
  14. Caio G, Volta U, Sapone A, Leffler DA, De Giorgio R, Catassi C, et al. Celiac disease: a comprehensive current review. BMC Med. 2019;17(1):142. [Crossref]  [PubMed]  [PMC] 
  15. Rashtak S, Murray JA. Review article: coeliac disease, new approaches to therapy. Aliment Pharmacol Ther. 2012;35(7):768-81. [Crossref]  [PubMed]  [PMC] 
  16. Lee AR, Wolf RL, Lebwohl B, Ciaccio EJ, Green PHR. Persistent economic burden of the gluten free diet. Nutrients. 2019;11(2):399. [Crossref]  [PubMed]  [PMC] 
  17. Parkes M, Cortes A, van Heel DA, Brown MA. Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat Rev Genet. 2013;14(9):661-73. [Crossref]  [PubMed] 
  18. Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med. 1997;3(7):797-801. [Crossref]  [PubMed] 
  19. Malheiro AJ, Dean LC, Hoeppner MA, Lyoshin V, Gu B, Chen C, et al. How the NIH Genetic Testing Registry and Medical Genetics Summaries can help oncologists adopt pharmacogenetics guidelines. 2020;38(15 Suppl):e14141. [Crossref] 
  20. Ronquillo JG, Weng C, Lester WT. Assessing the readiness of precision medicine interoperabilty: an exploratory study of the National Institutes of Health genetic testing registry. J Innov Health Inform. 2017;24(4):918. [Crossref]  [PubMed]  [PMC] 
  21. Rubinstein WS, Maglott DR, Lee JM, Kattman BL, Malheiro AJ, Ovetsky M, et al. The NIH genetic testing registry: a new, centralized database of genetic tests to enable access to comprehensive information and improve transparency. Nucleic Acids Res. 2013;41(Database issue):D925-35. [Crossref]  [PubMed]  [PMC] 
  22. Vanga RR, Kelly CP. Novel therapeutic approaches for celiac disease. Discov Med. 2014;17(95):285-93. [PubMed] 
  23. Tack GJ, van de Water JM, Bruins MJ, Kooy-Winkelaar EM, van Bergen J, Bonnet P, et al. Consumption of gluten with gluten-degrading enzyme by celiac patients: a pilot-study. World J Gastroenterol. 2013;19(35):5837-47. [Crossref]  [PubMed]  [PMC] 
  24. Gottlieb K, Dawson J, Hussain F, Murray JA. Development of drugs for celiac disease: review of endpoints for Phase 2 and 3 trials. Gastroenterol Rep (Oxf). 2015;3(2):91-102. [Crossref]  [PubMed]  [PMC] 
  25. Tye-Din JA, Galipeau HJ, Agardh D. Celiac disease: a review of current concepts in pathogenesis, prevention, and novel therapies. Front Pediatr. 2018;6:350. [Crossref]  [PubMed]  [PMC] 
  26. Lähdeaho ML, Kaukinen K, Laurila K, Vuotikka P, Koivurova OP, Kärjä-Lahdensuu T, et al. Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease. Gastroenterology. 2014;146(7):1649-58. [Crossref]  [PubMed] 
  27. Syage JA, Green PHR, Khosla C, Adelman DC, Sealey-Voyksner JA, Murray JA. Latiglutenase treatment for celiac disease: symptom and quality of life ımprovement for seropositive patients on a gluten-free diet. GastroHep. 2019;1(6):293-301. [Crossref]  [PubMed]  [PMC] 
  28. Wolf C, Siegel JB, Tinberg C, Camarca A, Gianfrani C, Paski S, et al. Engineering of Kuma030: a gliadin peptidase that rapidly degrades immunogenic gliadin peptides in gastric conditions. J Am Chem Soc. 2015;137(40):13106-13. [Crossref]  [PubMed]  [PMC] 
  29. Pultz IS, Hill M, Vitanza JM, Wolf C, Saaby L, Liu T, et al. Gluten degradation, pharmacokinetics, safety, and tolerability of tak-062, an engineered enzyme to treat celiac disease. Gastroenterology. 2021;161(1):81-93.e3. [Crossref]  [PubMed] 
  30. Pultz IS, Leffler D, Liu T, Winkle P, Vitanza J, Hill M. 1125 KUMA062 effectively digests gluten in the human stomach: results of a phase 1 study. Gastroenterology. 2020;158(6):S-218. [Crossref] 
  31. Rauhavirta T, Oittinen M, Kivistö R, Männistö PT, Garcia-Horsman JA, Wang Z, et al. Are transglutaminase 2 inhibitors able to reduce gliadin-induced toxicity related to celiac disease? A proof-of-concept study. J Clin Immunol. 2013;33(1):134-42. [Crossref]  [PubMed] 
  32. Cengiz C. Çölyak hastalığında yeni terapötik yaklaşımlar [New therapeutic approaches in celiac disease]. Güncel Gastroenteroloji. 2010;14(4):198-201.
  33. Alhassan E, Yadav A, Kelly CP, Mukherjee R. Novel nondietary therapies for celiac disease. Cell Mol Gastroenterol Hepatol. 2019;8(3):335-45. [Crossref]  [PubMed]  [PMC] 
  34. Ventura MAE, Sajko K, Hils M, Pasternack R, Greinwald R, Tewes B, et al. Su1161-the oral transglutaminase 2 (TG2) inhibitor Zed1227 blocks TG2 activity in a mouse model of intestinal inflammation. Gastroenterology. 2018;154(6):S-490. [Crossref] 
  35. Shalimar, Das P, Sreenivas V, Datta Gupta S, Panda SK, Makharia GK. Effect of addition of short course of prednisolone to gluten-free diet on mucosal epithelial cell regeneration and apoptosis in celiac disease: a pilot randomized controlled trial. Dig Dis Sci. 2012;57(12):3116-25. [Crossref]  [PubMed] 
  36. Ciacci C, Maiuri L, Russo I, Tortora R, Bucci C, Cappello C, et al. Efficacy of budesonide therapy in the early phase of treatment of adult coeliac disease patients with malabsorption: an in vivo/in vitro pilot study. Clin Exp Pharmacol Physiol. 2009;36(12):1170-6. [Crossref]  [PubMed] 
  37. Therrien A, Silvester JA, Leffler DA, Kelly CP. Efficacy of enteric-release oral budesonide in treatment of acute reactions to gluten in patients with celiac disease. Clin Gastroenterol Hepatol. 2020;18(1):254-6. [Crossref]  [PubMed]  [PMC] 
  38. Mukewar SS, Sharma A, Rubio-Tapia A, Wu TT, Jabri B, Murray JA. Open-capsule budesonide for refractory celiac disease. Am J Gastroenterol. 2017;112(6):959-67. [Crossref]  [PubMed] 
  39. Marasco G, Cirota GG, Rossini B, Lungaro L, Di Biase AR, Colecchia A, et al. Probiotics, prebiotics and other dietary supplements for gut microbiota modulation in celiac disease patients. Nutrients. 2020;12(9):2674. [Crossref]  [PubMed]  [PMC] 
  40. Cristofori F, Indrio F, Miniello VL, De Angelis M, Francavilla R. Probiotics in celiac disease. Nutrients. 2018;10(12):1824. [Crossref]  [PubMed]  [PMC] 
  41. Galipeau H, McCarville JL, Moeller S, Murray JA, Alaedini A, Jabri B, et al. Tu1749 Gluten-Induced Responses in NOD/DQ8 Mice Are Influenced by Bacterial Colonization. Gastroenterology. 2014;5 Supplement 1(146):S-833. [Crossref] 
  42. D'Arienzo R, Maurano F, Luongo D, Mazzarella G, Stefanile R, Troncone R, et al. Adjuvant effect of Lactobacillus casei in a mouse model of gluten sensitivity. Immunol Lett. 2008;119(1-2):78-83. [Crossref]  [PubMed] 
  43. D'Arienzo R, Stefanile R, Maurano F, Mazzarella G, Ricca E, Troncone R, et al. Immunomodulatory effects of Lactobacillus casei administration in a mouse model of gliadin-sensitive enteropathy. Scand J Immunol. 2011;74(4):335-41. [Crossref]  [PubMed] 
  44. Lindfors K, Blomqvist T, Juuti-Uusitalo K, Stenman S, Venäläinen J, Mäki M, et al. Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture. Clin Exp Immunol. 2008;152(3):552-8. [Crossref]  [PubMed]  [PMC] 
  45. Papista C, Gerakopoulos V, Kourelis A, Sounidaki M, Kontana A, Berthelot L, et al. Gluten induces coeliac-like disease in sensitised mice involving IgA, CD71 and transglutaminase 2 interactions that are prevented by probiotics. Lab Invest. 2012;92(4):625-35. [Crossref]  [PubMed] 
  46. Klemenak M, Dolin?ek J, Langerholc T, Di Gioia D, Mičetić-Turk D. Administration of Bifidobacterium breve decreases the production of TNF-α in children with celiac disease. Dig Dis Sci. 2015;60(11):3386-92. [Crossref]  [PubMed] 
  47. Francavilla R, Piccolo M, Francavilla A, Polimeno L, Semeraro F, Cristofori F, et al. Clinical and microbiological effect of a multispecies probiotic supplementation in celiac patients with persistent IBS-type symptoms: a randomized, double-blind, placebo-controlled, multicenter trial. J Clin Gastroenterol. 2019;53(3):e117-25. [Crossref]  [PubMed]  [PMC] 
  48. Helmby H. Human helminth therapy to treat inflammatory disorders-where do we stand? BMC Immunol. 2015;16:12. [Crossref]  [PubMed]  [PMC] 
  49. Croese J, Gaze ST, Loukas A. Changed gluten immunity in celiac disease by Necator americanus provides new insights into autoimmunity. Int J Parasitol. 2013;43(3-4):275-82. [Crossref]  [PubMed] 
  50. McSorley HJ, Gaze S, Daveson J, Jones D, Anderson RP, Clouston A, et al. Suppression of inflammatory immune responses in celiac disease by experimental hookworm infection. PLoS One. 2011;6(9):e24092. [Crossref]  [PubMed]  [PMC] 
  51. Croese J, Giacomin P, Navarro S, Clouston A, McCann L, Dougall A, et al. Experimental hookworm infection and gluten microchallenge promote tolerance in celiac disease. J Allergy Clin Immunol. 2015;135(2):508-16. [Crossref]  [PubMed] 
  52. Pinier M, Fuhrmann G, Galipeau HJ, Rivard N, Murray JA, David CS, et al. The copolymer P(HEMA-co-SS) binds gluten and reduces immune response in gluten-sensitized mice and human tissues. Gastroenterology. 2012;142(2):316-25.e1-12. [Crossref]  [PubMed] 
  53. McCarville JL, Nisemblat Y, Galipeau HJ, Jury J, Tabakman R, Cohen A, et al. BL-7010 demonstrates specific binding to gliadin and reduces gluten-associated pathology in a chronic mouse model of gliadin sensitivity. PLoS One. 2014;9(11):e109972. [Crossref]  [PubMed]  [PMC] 
  54. ClinicalTrials.gov [Internet]. [Cited: April 6, 2022]. Safety and Systemic Exposure Study of BL-7010 in Well-Controlled Celiac Patients.-Full Text View. Available from: [Link] 
  55. Freitag TL, Podojil JR, Pearson RM, Fokta FJ, Sahl C, Messing M, et al. Gliadin nanoparticles induce immune tolerance to gliadin in mouse models of celiac disease. Gastroenterology. 2020;158(6):1667-81.e12. [Crossref]  [PubMed]  [PMC] 
  56. Kelly C, Murray J, Leffler DA, Bledsoe A, Smithson G, Podojil JR, et al. CNP-101 Prevents Gluten Challenge Induced Immune Activation in Adults with Celiac Disease. United European Gastroenterology Journal. 2019;7 Issue 8(Supplement). [Link] 
  57. ClinicalTrials.gov [Internet]. [Cited: April 6, 2022]. Search of: NCT03486990-List Results. Available from: [Link] 
  58. Castillo NE, Leffler DA. Celiac disease as a model disorder for testing novel autoimmune therapeutics. The Value of BCG and TNF in Autoimmunity. 1st ed. Cambridge, Massachusetts: Academic Press; 2014. p.126-39. [Crossref] 
  59. Gopalakrishnan S, Tripathi A, Tamiz AP, Alkan SS, Pandey NB. Larazotide acetate promotes tight junction assembly in epithelial cells. Peptides. 2012;35(1):95-101. [Crossref]  [PubMed] 
  60. Paterson BM, Lammers KM, Arrieta MC, Fasano A, Meddings JB. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther. 2007;26(5):757-66. [Crossref]  [PubMed] 
  61. Leffler DA, Kelly CP, Abdallah HZ, Colatrella AM, Harris LA, Leon F, et al. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am J Gastroenterol. 2012;107(10):1554-62. [Crossref]  [PubMed]  [PMC] 
  62. Leffler DA, Kelly CP, Green PH, Fedorak RN, DiMarino A, Perrow W, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. 2015;148(7):1311-9.e6. [Crossref]  [PubMed]  [PMC] 
  63. Sample DA, Sunwoo HH, Huynh HQ, Rylance HL, Robert CL, Xu BW, et al. AGY, a novel egg yolk-derived anti-gliadin antibody, is safe for patients with celiac disease. Dig Dis Sci. 2017;62(5):1277-85. [Crossref]  [PubMed] 
  64. Palaniyappan A, Das D, Kammila S, Suresh MR, Sunwoo HH. Diagnostics of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid antigen using chicken immunoglobulin Y. Poult Sci. 2012;91(3):636-42. [Crossref]  [PubMed]  [PMC] 
  65. Gujral N, Löbenberg R, Suresh M, Sunwoo H. In-vitro and in-vivo binding activity of chicken egg yolk immunoglobulin Y (IgY) against gliadin in food matrix. J Agric Food Chem. 2012;60(12):3166-72. [Crossref]  [PubMed] 
  66. Lähdeaho ML, Scheinin M, Vuotikka P, Taavela J, Popp A, Laukkarinen J, et al. Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study. Lancet Gastroenterol Hepatol. 2019;4(12):948-59. [Crossref]  [PubMed] 
  67. Cellier C, Bouma G, van Gils T, Khater S, Malamut G, Crespo L, et al; RCD-II Study Group Investigators. Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study. Lancet Gastroenterol Hepatol. 2019;4(12):960-970. [PubMed] 
  68. Motta JP, Bermúdez-Humarán LG, Deraison C, Martin L, Rolland C, Rousset P, et al. Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Sci Transl Med. 2012;4(158):158ra144. [Crossref]  [PubMed] 
  69. Galipeau HJ, Wiepjes M, Motta JP, Schulz JD, Jury J, Natividad JM, et al. Novel role of the serine protease inhibitor elafin in gluten-related disorders. Am J Gastroenterol. 2014;109(5):748-56. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com